Stephens Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price target reduced by equities researchers at Stephens from $7.00 to $5.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Stephens’ price objective indicates a potential upside of 16.55% from the stock’s current price.

A number of other brokerages have also commented on HCAT. Canaccord Genuity Group decreased their price objective on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Wells Fargo & Company decreased their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 21st. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research report on Wednesday, January 8th. Piper Sandler reduced their price target on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reduced their price target on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.27.

Health Catalyst Stock Down 3.2 %

Shares of HCAT opened at $4.29 on Thursday. The firm has a market capitalization of $301.21 million, a price-to-earnings ratio of -3.18 and a beta of 1.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The business’s fifty day moving average price is $5.73 and its two-hundred day moving average price is $7.16. Health Catalyst has a 52 week low of $3.76 and a 52 week high of $9.24.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.51, for a total value of $39,119.59. Following the sale, the chief operating officer now owns 91,253 shares of the company’s stock, valued at $685,310.03. This trade represents a 5.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Linda Llewelyn sold 6,442 shares of Health Catalyst stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $7.88, for a total value of $50,762.96. Following the completion of the sale, the insider now directly owns 98,702 shares in the company, valued at $777,771.76. This represents a 6.13 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,243 shares of company stock worth $273,620. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Health Catalyst

Several hedge funds and other institutional investors have recently modified their holdings of HCAT. Janney Montgomery Scott LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at about $897,000. Fred Alger Management LLC acquired a new position in Health Catalyst during the third quarter worth approximately $6,858,000. Millrace Asset Group Inc. acquired a new position in Health Catalyst during the third quarter worth approximately $1,568,000. Point72 Asset Management L.P. increased its position in Health Catalyst by 69.4% during the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after buying an additional 211,805 shares during the last quarter. Finally, Impax Asset Management Group plc increased its position in Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after buying an additional 360,201 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.